6533b82efe1ef96bd1293d71

RESEARCH PRODUCT

Length of remdesivir treatment in patients with severe COVID-19

Mariachiara IppolitoAndrea Cortegiani

subject

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)RC705-779Journal Clubbusiness.industry4Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RemdesivirMEDLINEExpert Opinion03 medical and health sciencesRegimenDiseases of the respiratory system0302 clinical medicine030228 respiratory systemSAFERMedicineIn patient030212 general & internal medicinebusinessBit (key)

description

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has caused more than 96 million cases and over 2 million deaths worldwide as of January 21, 2021. As the crisis continues, the scientific community, institutions and pharmaceutical industries are striving to find effective therapies to prevent or treat the disease. Remdesivir (GS-5734) was early identified as an option.

10.1183/20734735.0276-2020http://breathe.ersjournals.com/content/17/1/200276.full